Product Images Alendronate Sodium

View Photos of Packaging, Labels & Appearance

Product Label Images

The following 11 images provide visual information about the product associated with Alendronate Sodium NDC 65862-329 by Aurobindo Pharma Limited, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

Figure 1 - alendronate fig1

Figure 1 - alendronate fig1

This is a chart showing the cumulative incidence of hip fractures over 10% for patients with radiographic vertebral fracture at baseline in a three-year study of FIT. The chart compares the incidence rates between the placebo group and the alendronate sodium group over time in months.*

PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 70 mg Blister Carton (4 Unit-of-use) - alendronate fig10

PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 70 mg Blister Carton (4 Unit-of-use) - alendronate fig10

This appears to be a mixture of jumbled up text with different topics. Therefore, the description cannot be generated.*

Figure 2 - alendronate fig2

Figure 2 - alendronate fig2

This text presents the mean % increase in bone mineral density (BMD) relative to placebo, in studies for osteoporosis treatment in postmenopausal women. The specific treatment mentioned is alendronate 10mg/day, with an increase in BMD of 12% at three years. The increase in BMD is noted for the lumbar spine, femoral neck, and trochanter.*

Figure 3 - alendronate fig3

Figure 3 - alendronate fig3

This is a description of a study on the effect of Alendronate 10mg/day versus the placebo in treating osteoporosis in postmenopausal women. The study was conducted in multiple countries and involved measuring the percentage change of bone mineral density (BMD) in the lumbar spine from the baseline. The time course of the effect was evaluated over 36 months. The results were presented in a graph with the mean % change from baseline and standard error (SE) plotted against time in months for both the Alendronate 10mg/day and placebo groups.*

Figure 4 - alendronate fig4

Figure 4 - alendronate fig4

Figure 5 - alendronate fig5

Figure 5 - alendronate fig5

Figure 6 - alendronate fig6

Figure 6 - alendronate fig6

The text refers to a study that analyzed the effect of Alendronate on serum alkaline phosphatase in patients with Paget's Disease of Bone. The study compared the results of patients who took Alendronate 40mg/day with those who took a placebo or Etidronate 400mg/day. The data shows the mean % change from baseline over a period of 6 months, with measurements taken at 0, 3, and 6 months. There were two separate studies, one multinational and another conducted in the US, with N=27 and N=41, respectively.*

PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 10 mg (30 Tablets Bottle) - alendronate fig7

PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 10 mg (30 Tablets Bottle) - alendronate fig7

This is a medication called Alendronate Sodium in the form of tablets, available only with a prescription. Each tablet contains 13.052 mg of alendronate sodium USP, equivalent to 10 mg of alendronic acid. It is distributed by a company called Aurobindo Pharma based in New Jersey. The recommended adult dosage is 10mg to be taken once per day. The medication should be stored in a well-closed container at a temperature range of 20-25°C (68-77°F), with excursions permitted to 15-30°C (59-86°F). A medication guide has to be provided to every patient purchasing the tablets.*

PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 10 mg Blister Carton 100 (10 x 10) Unit-dose Tablets - alendronate fig8

PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 10 mg Blister Carton 100 (10 x 10) Unit-dose Tablets - alendronate fig8

This is a medicine description for Alendronate Sodium Tablets that come in a unit-dose package of 100 (10 x 10) tablets. Each tablet contains 13,052 mg alendronate sodium USP equivalent to 10 mg alendronic acid. The usual adult dosage is 10 mg once a day, and there are important instructions for use of the medicine that can be found in the accompanying Medication Guide. Pharmacists are instructed to dispense the guide to each patient. The package is child-resistant and it is important to keep all drugs out of the reach of children. The tablets should be stored at 20° to 25°C (68° to 77°F), but excursions are permitted to 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature]. The drugs are distributed by Aurobindo Pharma USA, Inc. and were made in India.*

PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 35 mg Blister Carton (4 Unit-of-use) - alendronate fig9

PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 35 mg Blister Carton (4 Unit-of-use) - alendronate fig9

Chemical Structure - alendronate str

Chemical Structure - alendronate str

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.